中文摘要
目前臨床醫學治療，醫生對於患者給藥一般會依據臨床經驗，加上各種生化檢驗數據來做給藥判斷，但生化檢驗只能提供一般初步生理反應數據，雖然足夠提供醫生對疾病的判斷，而對於用藥部份並沒有太大的幫助，因此醫生會依據傳統臨床用藥經驗，採用嘗試錯誤的醫療給藥方式。使用第一線藥品或低價、低劑量藥品進行治療，如此將會造成醫療時效延長、患者醫療品質降低，或產生嚴重副作用，並會讓用藥成本增加。因此可利用基因多型性檢測模式輔助，進行基因多型性﹙SNP﹚分析，確認基因類型就可預測用藥結果，並與現有的生化診斷體系接軌，加速檢驗醫學從表型診斷轉向基因型診斷，並預防藥物副作用，提高療效，再進行藥物治療，進而加速治療效果、控制病情，減少藥物誤用或濫用的情況，節省健保用藥成本。
應用的方法：本研究以藥物基因學(Pharmacokinetic)角度探討一種可精確偵測糖尿病基因類型與預測用藥結果，能精確投藥之檢測方法，其特徵在於利用聚合酵素鏈鎖反應與限制酵素切割片段多型性等技術進行病人不同基因的多型性分析，再藉由單因子變異數分析ABCC8-E16基因多型性與第二型糖尿病藥物治療之影響，ABCC8-E16基因型的病患適合給予Sulfonylurea（磺基尿素類）降血糖藥物治療(P<0.05)，可將此結果提供醫師作為糖尿病藥物治療的參考依據，更可節省醫療院所給藥費用及縮短臨床用藥時間，對藥物臨床開發和未來的「個人化醫療」影響深遠。
第二型糖尿病, 磺基尿素類, 基因多型性檢測, 聚合酵素鏈鎖反應, 限制酵素切割片段多型性, 藥物基因學, 個人化醫療

Abstract
According to recent clinical treatment, doctors give patients medicines based on clinical experience and biochemical data. However, biochemical data simply provides an initial physiology reaction. Although the data is enough for doctors to diagnose diseases, it does not help much for doctors to indicate the most useful medicine. Therefore, doctors will use the first line, cheap or low dose medicine to cure patients by previous clinical experience. It will not only extend the time of treatment but also lower the medical quality. Not to mention the side effects and increases the cost. Consequently, using SNP（Single Nucleotide Polymorphism）will help doctors to find out different patients’ genotype and forecast the result of medicine. It will control disease efficiently and decrease the medical costs.
Methods: This study will be discussed with an accurate test of how to check the genotypes of diabetes mellitus and predict the result of treatment from pharmacogenetic. The method was using PCR (Polymerase Chain Reaction) and RFLP (Restriction Fragment Length Polymorphism) to analyze patients’ different genotype. Besides, this study uses the One-Way ANOVA to interpret the relationship between ABCC8-E16 and type 2 diabetes. In conclusion, the antidiabetic drugs- Sulfonylurea derivatives are suitable for ABCC8-E16 genotype patients. This result can be a reference for doctors to remedy diabetics. It will not only save the cost but also shorten the time of treatment, and it will impact deeply for personalized medicine in the future.

type 2 diabetes, Sulfonylurea, SNP, PCR, RFLP, pharmacogenetic, personalized medicine

目錄頁次
論文審書........................................................Ⅰ
致謝詞............................................................Ⅱ
中文摘要........................................................Ⅲ
Abstract .........................................................Ⅳ
圖目錄............................................................Ⅶ
表目錄............................................................Ⅷ
第一章 緒論.....................................................1
第一節 研究動機與背景.................................1
第二節 研究目的.............................................3
第三節 研究流程與架構.................................4
第四節 研究範圍與限制.................................6
第二章 文獻探討.............................................8
第一節 糖尿病形成的原因與分類.................8
第二節 糖尿病治療與藥物分析...................17
第三節 糖尿病檢測方式簡介 ......................38
第四節 市場分析及進入策略探討...............50
第三章 研究方法...........................................52
第一節 研究設計...........................................52
第二節 研究對象...........................................52
第三節 研究步驟...........................................54
第四節 研究方法...........................................55
第五節 統計方法...........................................62
第四章 資料分析與研究討論.......................63
第一節 利用本實驗方法及技術...................63
第二節 研究討論...........................................64
第三節 研究結果...........................................66
第四節 研究資料分析及研究探討...............67
第五章 市場分析...........................................69
第一節 市場定位...........................................70
第二節 市場導入策略與運用.......................73
第三節 市場1%佔有率的攻掠策略.............75
第六章 討論與建議.......................................80
附件
同意書............................................................84
參考文獻........................................................89
中文文獻........................................................89
英文文獻........................................................91

參考文獻
中文部分
1.行政院衛生署:http://www.doh.gov.tw/New Version/List.asp.
2.行政院主計處:http://sowf.moi.gov.tw/stat/month/m1-06.xls.
3.行政院衛生署國民局:http://www.bhp.doh.gov.tw/BHP/do/www/themePark
DocRead?theme ParkDocumentId=2651&type=document&themeParkId=27
4.布萊恩．史比爾（Brian B. Spear）、馬哥．希斯奇歐齊（Margo Heath-Chiozzi）與傑佛瑞．哈夫（Jeffrey Huff）合撰的《遺傳藥理學的臨床應用》（Clinical Application of Pharmacogenetics），文章刊載在2001年5月的《分子醫學趨勢》（Treds in Molecular Medicine）。
5.林宏達:論述血糖控制與糖尿病合併症。中華民國內分泌暨糖尿病學會會訊。1995; 12: 1-4
6.呂榮國。糖尿病神經病變。當代醫學 2002; 29: 819-824。
7.企業競爭優勢 方至民 前程企管出版
8.告別糖尿病─高健智著 先見出版公司8.島田和典、前田秀一郎。遺傳基因診斷:原理與應用。合記圖書出版社。2002: 26-29。
9.哈佛商業評論 遠見雜誌出版
10.新基因學的治理與政策議題 賴沅暉 行政暨政策學報 第三十八期
2004: 61&#8764;94。 布萊恩．史比爾（Brian B. Spear）、馬哥．希斯奇歐齊（Margo Heath-Chiozzi）
11.認識糖尿病─王麗芬主編 國家出版社
12.糖尿病 朝陽堂
13.糖尿病治療手冊─鍾壁和著 笛藤出版社
14.糖尿病的防治 徐氏基金會出版
15.糖尿病的防治與食療 聯廣圖書公司
16.糖尿病的認識與防治 楊旭平
17.賴婕瑄。口服降血糖藥用藥指導。藥學雜誌 2003; 19: 20-28。
18.張乃文、吳俊鋒、劉文俊。新一代的胰島素治療－胰島素類似物。基層醫學 2004; 19(4): 80-85
19.唐正乾、周昌樺、徐維信、蔡東榮。糖尿病照護藥物的新發展。內科學誌 2003; 14(5): 23-34。

英文部份
1.American Diabetes Association. Hyperglycemic crises in patients with
diabetes mellitus. Diabetes Care. 2001; 24(1): 154-161.
2.American Diabetes Association. Report of the expert committee on the
diagnosis and classification of diabetes mellitus. Diabetes Care 2001; 24 supp1: S5-S19.
3.American Diabetes Association. Standards of Medical Care for Patients With Diabetes Mellitus. Diabetes Care 2001; 24 suppl1: S33-S43.
4.American Diabetes Association. Nutrition Recommendations and Principles for People With Diabetes Mellitus.Diabetes Care. 2001; 24 suppl1: S44-S47.
5.American Diabetes Association. Diabetes Mellitus and Exercise. Diabetes Care 2001; 24 suppl1: S51-S55.
6.American Diabetes Association. Diabetic retinopathy. Diabetes Care 2001; 24 supp11: S73-S76.
7.American Diabetes Association. Clinical practice recommendations 2002. Diabetes Care 2002; 25 supp1: S21-S24.
8.American Diabetes Association. Nephropathy in diabetes(Position Statement). Diabetes Care 2004; 27 supp1: S79-S83.
9.American Diabetes Association. Screening for Type 2 Diabetes. Diabetes Care 2004; 27 supp1: S11-S14.
10.Amos A.F, McCarty D.J, Zimmet P. The rising global burden of diabetes and its complications to the year 2010. Diabet Med 1997; 14: S7-85.
11.Amon Zung, Benjamin Glaser, Revital Nimri, Zvi Zadik. Glibenclamide
treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J Clin Endocrinol Metab. 2004; 89(11): 5504-5507.
12.Andrew J. Krentz, Clifford J. Bailey. Oral antidiabetic agents current role in type 2 diabetes mellitus. Drugs 2005; 65(3): 385-411.
13.Ashcroft, Gribble. ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia 1999; 42: 903-919.
14.Bailey C.J, Robert C. Turner. Drug therapy: Metformin. N Eng J Med 1996;
334: 574-579.
15.Bloomgarden ZT. Nephropathy and neuropathy. American Diabetes
Association Annual Meeting 1999. Diabetes Care 2000; 23: 549-556.
16.Boyle J.P, Honeycutt A.A, Narayan K.M, Hoerger T.J, Geiss L.S, Chen H.
Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001; 24: 1936-1940.
17.Chiasson J-L, Josse R.G, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. The STOP-NIDDM Trial Research Group JAMA 2003; 290: 486-494.
18.Chuang L.M, Tsai S.T, Juang J.H, Tsai W.Y, Tai T.Y. Genetic Epidemiology of Type 1 Diabetes Mellitus in Taiwan. Diabetes Res Clin Pract 2000; 50(Suppl 2): S41-S47.
19.Charles R, Craig,Robert E, Stitzer.Modern Pharmacology with clinical
application 6th Edn. Williams & Wilkins, 2004: 763-776.
20.Cryer P.E, Fisher J.N, Shamoon H. Hypoglycemia (Technical Review). Dia-
betes Care 1994; 17: 734-755.
21.DeFronzo R.A.Pathogenesis of type 2 diabetes:metabolic and molecular
implications for identifying diabetes genes. Diabetes Reviews 1997; 5: 177-285.
22.DeFronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann
Intern Med 1999; 131: 281-303.
23.Dornhorst A. Insulotropic meglitinide analogues. Lancet 2001; 358: 1709-1715.
24.E.H. Hani, P. Boutin, E. Durand, H. Inoue, M.A. Permutt, G. Velho, P. Froguel. Missense mutations in the pancreatic islet beta cell inwardly rectifying K+ channel gene (KIR6.2/BIR ): a meta-analysis suggests a role in the polygenic basis of Type II diabetes mellitus in Caucasians. Diabetologia1998; 41: 1511-1515.
25.E J Para, C J Hoggart, C Bonilla, S Dios, J M Norris, J A Marshall, R F Hamman, R E Ferrell, P M McKeigue, M D Shriver. Relation of type 2 diabetes to individual admixture and candidate Gene polymorphisms in the Hispanic American population of San Luis Valley, Colorado. J Med Genet 2004; 41 :e116.
26.Eric T. Herffindal, Dick R. Gourley.Textbook of therapeutics drug and
disease management. 6th Edn, 1996: 360-361.
27.Eva-Maria D. Nielsen, Lars Hansen, Bendix Carstensen, Soren M. Echwald, Thomas Drivsholm, Charlotte Glumer, Birger Thorsteinsson, Knut Borch-Johnsen, Torben Hansen, Oluft Pedersen. The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes. Diabetes 2003; 52: 573-577.
28.Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment PanelIII). JAMA 2001; 285: 2486-2497.
29.Fedele D and Giugliano D: Peripheral diabetic neuropathy: current
recommendations and future prospects for its prevention and management. Drug 1997; 54: 414-421.
30.Fried L F, Orchard T J, Kasiske B L.Effect of lipid reduction on the progression of renal diesease: a meta-analysis. Kidney Int 2001; 59: 260-269.
31.Haffner SM, Lehto S, Ronnemaa T. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
32.Hani E H, Boutin P, Durand E, Inoue H, Permutt M A, Velho G, Froguel P
Missense mutations in the pancreatic islet beta cell inwardly rectifying K+ channel gene (KIR6.2/BIR): ameta-analysis suggests a role in the polygenic basis of type II diabetes mellitus in Caucasians. Diabetologia 1998; 41:1511–1515.
33.Hart L M, de Knijff P, Dekker J M, Stolk R P, Nijpels G, van der Does F E, Ruige J.B, Grobbee D.E, Heine R.J, Maassen J.A. Variants in the sulphonylurea receptor gene: association of the exon 16-3t variant with type II diabetes mellitus in Dutch Caucasian. Diabetologia 1999; 42: 617-620.
34.Holleman, Joost B.L. Hoekstra.Drug therapy: Insulin lispro. N Eng J Med 1997; 337: 176-183.
35.Holman R.R, Cull C.A, Turner R.C. A randomised double-blind trial of
acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44).Diabetes Care 1999; 22: 960-964.
36.Home, A. Lindholm, A. Riis. Insulin aspart vs. human insulin in the
management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Dia Med 2000; 17(11): 762-770.
37.Inoue H., Ferrer J., Welling C.M., Elbein S.C., Hoffman M., Mayorga R., Warren-Perry M., Zhang Y., Millns H., Turner R., Province M., Bryan J., Permutt M.A., and Aguilar-Bryan L. Sequence Variants in The Sulfonylurea Receptor (SUR) Gene Are Associated with NIDDM in Caucasians. Diabetes 1996; 45 (6): 825-83.
38.Irl B. Hirsch. Drug therapy:Insulin Analogues. N Eng1 J Med 2005; 352:
174-183.
39.Jones, J. L. DNA probes: Application in the food industry. Trend Food
Science Technology 1991; 2: 28-32.
40.Jorge L. Gross, Mirela J.de Azevedo, Sandra P. Silveiro, Luis Henrique
Canani, Maria Luiza Caramori, Themis Zelmanovitz. Diabetic nephropathy:diagnosis, prevention, and treatment. Diabetes Care 2005; 28(1): 164-176
41.Joseph T. Dipiro, Robert L. Talbert, Gary C. Yee, Gary R. Matzke, Barbara G. Wells, L. Michael Posey. PHARMACOTHERAPY:A Pathophysiology Apporach. 5th Edn, McGRAW-HILL 2002: 1336-1337.
42.Joshua A. Beckman, Mark A. Creager, Peter Libby. Diabetes and atherosclerosis: epidemiology, pathophysiology and management.
JAMA 2002; 287(19): 2570-2581.
43.Juraj Stanik, Daniela Gasperikova, Magdalena Paskova, Lubomir Barak, Jana Javorkova, Emilia Jancova,Miriam Ciljakova, Peter Hlava, Jozef Michalek, Sarah E. Flanagan, Ewan Pearson, Andrew T. Hattersley,Sian Ellard, Iwar Klimes. Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers. J Clin Endocrinol Metab 2007; 92(4): 1276-1282
44.King H, Aubert R.E, Herman W.H.Global burden of diabetes,1995-2025
:prevalence, numerical estimates, and projections. Diabetes Care 1998
;21:1414-1431.
45.King H.Global estimates for prevalence of diabetes mellitus and impaired glucoseTolerance in adults. Diabetes Care 1993; 16: 157-177.
46.Kitabchi A.E, Umpierrez G.E, Murphy M.B, Barrett E.J, Kreisberg R.A, Malone J.I, Wall B.M. Management of hyperglycemic crises in patients with diabetes. Diabetes Care 2001; 24(1): 131-153.
47.Krentz A.J, Ferner R.E, Bailey C.J. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994; 11: 223-241.
48.Krentz A.J, Bailey C.J, Melander A. Thiazolidinediones for type 2 diabetes. BMJ 2000; 321: 252-253.
49.Kuusisto J, Mykkanen L, Pyorala K, Laakso M. Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke 1994; 25: 1157-1164.
50.Lebovitz H.E. α-Glucosidase inhibitors as agents in the treament of diabetes. Diabetes Revs 1998; 6: 132-145.
51.L.M. `t Hart, P. de Knijff, J.M. Dekker, R.P. Stolk, G. Nijpels, F.E.E. van der Does, J.B. Ruige, D.E. Grobbee, R.J. Heine, J.A. Maassen1.Variants in the sulphonylurea receptor gene:association of the exon 16-3t variant with Type II diabetes mellitus in Dutch Caucasians. Diabetologia 1999; 42: 617-620.
52.Logminiene Z, Norkus A, Valius L. Direct and indirect diabetes costs in the world. Medicina 2004; 40(1): 16-26.
53.Mark A. Sperling, ATP-Sensitive Potassium Channels -Neonatal DiabetesMellitus and Beyond. N ENGL J Med 2006; 355(5): 507-510.
54.Mayfield J.A, Reiber G.E, Sanders L.J, Janisse D, Pogach L.M. Preventive Foot Care in People With Diabetes. Diabetes Care 1998; 21: 2161-2177.
55.Melissa F. Green, Zarrintaj Aliabadi, Bryan T. Green. Diabetic Foot: Evaluation and Management. South Med J 2002; 95(1): 95-101.
56.Miki T, Nagashima K, and Seino S. Review: The Structure and Function of The ATP-Sensitive K+ Channel in Insulin-Secreting Pancreatic B-Cells .Journal of Molecular Endocrinology 1999; 22 (2): 113-124.
57.M Lepore, S Pampanelli, C Fanelli, F Porcellati, L Bartocci, A Di Vincenzo, C Cordoni, E Costa, P Brunetti, GB Bolli.Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148.
58.Mogensen C.E. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Intern Med 2003; 254: 45-66.
59.Nielsen E.M, Hansen L, Carstensen B, Echwald SM, Drivsholm T,Glumer C, Thorsteinsson B, Borch-Johnsen K, Hansen T, Pedersen O .The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes. Diabetes 2003; 52: 573–577.
60.N. Shaat . M. Ekelund . &Aring;. Lernmark . S. Ivarsson .P. Almgren . K. Berntorp . L. Groop. Association of the E23K polymorphism in the KCNJ11 gene with gestational diabetes mellitus. Diabetologia 2005; 48: 2544–2551.
61.Rendell M. The role of sulfonylureas in the management of type 2 diabetes. Drug 2004; 64(12): 1339-1358.
62.Schwanstecher C, Meyer U, Schwanstecher M. KIR6.2 polymorphism pre-
disposes to type 2 diabetes by inducing overactivity of pancreatic β-cell ATP-sensitive K+channels. Diabetes 2002; 51: 875–879.
63.Seino S, Inagaki N, Gonoi T. Molecular biology of the beta cell ATP-
Sensitive K+ channel. Diabetes Rev 1996;4:177-190.
64.Seino S, Miki T.Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog Biophys Mol Biol 2003; 81: 133-176.
65.The diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng1 J Med 1993; 329: 977-986.
66.UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-sugar control with sulphonylureas or insulin compared with conventions1 treatment in patients with type 2 diabetes(UKPDS 33). Lancet 1998; 352: 837-853.
67.UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in the overweight patients with type 2 diabetes(UKPDS 34) Lancet 1998; 352: 854-865.
68.Wandell PE, Tovi J, The quality of life of elderly diabetic patients.
J Diabetes Complication 2000; 14: 25-30.
69.Winder WW, Hardie DG. AMP-activated protein kinase, ametabolic master switch: possible roles in type 2 diabetes. Am J Physiol 1999; 277: E1-E10.
70.Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24: 758-767.